Fisher & Paykel Healthcare reported strong financial results for the second half of fiscal year 2026, with operating revenue up 14% to NZD 2.3 billion and net profit after tax up 24% to NZD 468.5 million.
Despite these gains, the stock saw a slight decline of 0.43%, closing at NZD 27.53, potentially reflecting external challenges such as U.S. tariffs and currency impacts.
The company’s leadership emphasized manufacturing efficiency and innovation as key drivers of growth.
Looking ahead, Fisher & Paykel Healthcare expects operating revenue between NZD 2.45 billion and NZD 2.57 billion for FY 2027.
